<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>1140</number>
    <updateDate>2022-11-01T19:47:17Z</updateDate>
    <updateDateIncludingText>2022-11-05T19:24:46Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <type>S</type>
    <introducedDate>2019-04-11</introducedDate>
    <congress>116</congress>
    <committees>
      <item>
        <systemCode>sshr00</systemCode>
        <name>Health, Education, Labor, and Pensions Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2019-04-11T14:35:57Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Protecting Access to Biosimilars Act of 2019</title>
        <congress>116</congress>
        <number>2011</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2019-04-02</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Lower Health Care Costs Act</title>
        <congress>116</congress>
        <number>1895</number>
        <type>S</type>
        <latestAction>
          <actionDate>2019-07-08</actionDate>
          <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 133.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2019-04-11</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2019-04-11</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>S001203</bioguideId>
        <fullName>Sen. Smith, Tina [D-MN]</fullName>
        <firstName>Tina</firstName>
        <lastName>Smith</lastName>
        <party>D</party>
        <state>MN</state>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>C001075</bioguideId>
        <fullName>Sen. Cassidy, Bill [R-LA]</fullName>
        <firstName>Bill</firstName>
        <lastName>Cassidy</lastName>
        <party>R</party>
        <state>LA</state>
        <sponsorshipDate>2019-04-11</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>C001096</bioguideId>
        <fullName>Sen. Cramer, Kevin [R-ND]</fullName>
        <firstName>Kevin</firstName>
        <lastName>Cramer</lastName>
        <party>R</party>
        <state>ND</state>
        <sponsorshipDate>2019-05-07</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Allergies</name>
        </item>
        <item>
          <name>Blood and blood diseases</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Health promotion and preventive care</name>
        </item>
        <item>
          <name>Health technology, devices, supplies</name>
        </item>
        <item>
          <name>Immunology and vaccination</name>
        </item>
        <item>
          <name>Licensing and registrations</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2019-04-11</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2020-03-05T22:51:59Z</updateDate>
        <text><![CDATA[ <p><b>Protecting Access to Biosimilars Act of 2019</b></p> <p>This bill excludes biological products that were initially licensed under the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (e.g., insulin) from the exclusivity protections that delay the licensure of biosimilar products under the Public Health Service Act (PHS Act). (The Biologics Price Competition and Innovation Act of 2009 generally requires that biological products approved under the FD&amp;C Act are treated as though they were approved under the PHS Act through March 23, 2020.)</p>]]></text>
      </summary>
    </summaries>
    <title>Protecting Access to Biosimilars Act of 2019</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Protecting Access to Biosimilars Act of 2019</title>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>Protecting Access to Biosimilars Act of 2019</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009.</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2019-04-11T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-116s1140is/xml/BILLS-116s1140is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2019-04-11</actionDate>
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
